Endocrine最新文献

{"title":"The diagnostic dilemma of adrenal vascular tumors: analysis of 21 cases and systematic review of the literature.","authors":"Kimberly Coscia, Caterina Ravaioli, Lorenzo Tucci, Giacomo Colombin, Francesca Donnarumma, Cristina Mosconi, Caterina Balacchi, Cristina Nanni, Laura Alberici, Saverio Selva, Uberto Pagotto, Donatella Santini, Giovanni Tallini, Guido Di Dalmazi, Valentina Vicennati, Antonio De Leo","doi":"10.1007/s12020-024-04123-5","DOIUrl":"10.1007/s12020-024-04123-5","url":null,"abstract":"<p><strong>Purpose: </strong>Adrenal vascular tumors are mainly represented by adrenal cavernous hemangiomas (ACHs) and adrenal cystic lymphangiomas (ACLs). Their radiological features often overlap with malignant tumors, therefore ruling out malignancy becomes mandatory. We analyzed clinical, radiological, and histopathological data to identify specific characteristics of these tumors.</p><p><strong>Methods: </strong>We reviewed 21 patients with ACHs (n = 12), ACLs (n = 8), or adrenal cysts (n = 1) confirmed by histopathology. We selected 82 papers from PubMed to provide a systematic review of the literature.</p><p><strong>Results: </strong>In our cohort, median age at diagnosis was 58 years, with sex evenly distributed. All tumors were unilateral (median size = 44 mm), with 6 cases of increasing tumor size. All tumors exhibited non-contrast CT density > 10 Hounsfield Unit (HU). Calcifications were found in 5 cases. Hormonal studies revealed 11 non-functioning tumors and 2 cortisol-secreting tumors. Elevated urinary metanephrines were found in 2 cases. Immunostaining showed CD31/CD34/factor VIII expression in ACHs (n = 5, 24%) and podoplanin expression in ACLs (n = 6, 29%). The literature review revealed 71 reported cases of ACHs and 104 reported cases of ACLs. Median age at diagnosis was 46 years, with slightly female prevalence (63%). Median tumor size was 48 mm. 84 cases were symptomatic, with life-threatening hemorrhage reported in only 3 patients. Calcifications were found in 23% of cases. Surgical approaches varied, with open and laparoscopic adrenalectomy performed in 55 and 42 patients respectively.</p><p><strong>Conclusions: </strong>ACHs and ACLs represent a diagnostic dilemma in clinical practice due to their rarity and their misleading imaging features.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"1291-1304"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus.","authors":"Eleni-Rafaela Kani, Eleftheria Karaviti, Dimitra Karaviti, Eleni Gerontiti, Ioanna A Paschou, Katerina Saltiki, Katerina Stefanaki, Theodora Psaltopoulou, Stavroula A Paschou","doi":"10.1007/s12020-024-04050-5","DOIUrl":"10.1007/s12020-024-04050-5","url":null,"abstract":"<p><p>Immune Checkpoint Inhibitors (ICIs) have revolutionized cancer treatment, offering hope for patients with various malignancies. However, along with their remarkable anticancer effects, ICIs can also trigger immune-related adverse events (irAEs). One such noteworthy complication is the development of Diabetes Mellitus (DM), which particularly resembles Type 1 Diabetes Mellitus (T1DM). The aim of this review is to provide insights into the epidemiology, pathophysiology, diagnostic issues, and treatment considerations of ICI-induced DM (ICI-DM), emphasizing the importance of early recognition and management to mitigate adverse outcomes. Although still rare, the incidence has increased with the widespread use of ICIs, especially PD-1/PD-L1 blockers (from 0.2% to 1.9%). Factors affecting the development of ICI-DM, such as specific ICIs, patient demographics, and genetic predispositions, are discussed. The complex interplay between immune dysregulation and pancreatic β-cell destruction contributes to diagnostic challenges, with presentations varying from asymptomatic hyperglycemia to diabetic ketoacidosis (DKA). Management strategies prioritize meticulous glycemic and electrolyte regulation along with tailored intravenous insulin therapy in cases of DKA. DM remission is rare, therefore treatment with both long-acting insulin at bedtime and short-acting insulin before meals is needed in longterm. Total daily insulin requirements can be estimated at 0.3-0.4 units/kg/day for most patients as a starting dose.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"875-890"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variations, clinical presentation and treatment outcome of isolated growth hormone deficiency type I and II: case series and review of the literature.","authors":"Ran Li, Yiying Yang, Xudong Bao, Meiping Chen, Hongbo Yang, Fengying Gong, Hanze Du, Hui Pan, Huijuan Zhu","doi":"10.1007/s12020-024-04102-w","DOIUrl":"10.1007/s12020-024-04102-w","url":null,"abstract":"<p><strong>Purpose: </strong>To report a case series of four patients with isolated growth hormone deficiency (IGHD) type I from two Chinese pedigrees and to elucidate phenotype-genotype correlation of IGHD type I and II with GH1 gene alterations in the literature.</p><p><strong>Methods: </strong>Whole exome sequencing (WES) was performed and a literature review was conducted.</p><p><strong>Results: </strong>Four patients presented with extreme growth retardation (height -4.74 to -6.50 SDS) and undetectable peak growth hormone (GH) during GH stimulating test. WES revealed a novel homozygous nonsense mutation, c.316delC (p.L106Cfs*35), in GH1 gene in the the first pedigree. Deletions of exon 1-5 in GH1 gene were identified in the second pedigree. Ideal catch-up growth after GH treatment was achieved. 94 patients with IGHD type I and 240 patients with IGHD type II were included in literature review. Patients with IGHD type I exhibited younger age (3.2 vs 6.0 years, P < 0.001), more severe growth retardation (median height -6.50 vs -3.84 SDS, P < 0.001), lower peak GH levels (0.05 vs 1.70 ng/ml, P < 0.001) and a higher dosage of GH (0.22 vs 0.17 mg/kg/week, P = 0.012) compared to patients with IGHD type II. Gross deletions constituted 72.3% of IGHD type I cases, while splicing mutations and missense mutations comprised 54.2% and 45.0% of IGHD type II cases. In patients with IGHD type I harboring gross deletion, an early age of diagnosis correlated with both a higher height SDS at diagnosis and a better response after GH treatment. Height SDS after GH treatment in patients with IGHD type II carrying splicing mutations was negatively correlated with age at diagnosis.</p><p><strong>Conclusion: </strong>We identified two GH1 gene mutations, c.316delC (p.L106Cfs*35) and deletions of exon 1-5 in four Chinese patients with IGHD type I. They had a good response to GH treatment and gained satisfactory height improvement. Early diagnosis and initiating treatment may lead to a better prognosis.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"1171-1181"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoparathyroidism in adults with iron overload diseases (IOD): evidence of a subclinical phenotype.","authors":"Sara De Vincentis, Selene Evangelisti, Barbara Rossi, Maria Chiara Decaroli, Michela Locaso, Anna Ansaloni, Francesca Ferrara, Elena Corradini, Antonello Pietrangelo, Vincenzo Rochira","doi":"10.1007/s12020-024-04124-4","DOIUrl":"10.1007/s12020-024-04124-4","url":null,"abstract":"<p><strong>Purpose: </strong>To explore the prevalence of hypoparathyroidism (HPT), overt and subclinical, in a cohort of adults with Iron Overload Diseases (IOD). Secondary aim was to test the calcium (Ca)-to-phosphorus (P) ratio performance in identifying HPT.</p><p><strong>Methods: </strong>Single-center, prospective, case-control study. Sixty-five IOD, 40 with thalassemia major/intermedia (TMI) and 25 with hemochromatosis (HC), and 76 age-matched controls were included. Main outcomes (serum Ca, P, Ca/P ratio, intact parathyroid hormone (PTH), albumin) defined overt and subclinical HPT.</p><p><strong>Results: </strong>Albumin-adjusted Ca was lower (p = 0.004) and P higher (p = 0.002) comparing IOD to controls. Ca/P ratio was lower in IOD than controls (p < 0.001); PTH did not change. P was higher and Ca/P lower comparing TMI to HC and controls (p < 0.001); Ca did not change. A total of 28/65 IOD (43%) had HPT (9.2% overt, 33.8% subclinical) whose prevalence was higher in TMI than HC (p < 0.001). Ca/P ratio <2.32 had sensitivity 71.4% and specificity 83.9% in detecting overt/subclinical HPT. IOD with Ca/P ratio <2.32 (1.78 in SI) had an almost 12-fold increased likelihood to be affected by HPT (OR 12.92 [3.90-42.82]; p < 0.001). Ca/P (p = 0.002) was the only independent risk factor for HPT at multivariate analysis.</p><p><strong>Conclusions: </strong>HPT, especially non-classical subclinical HPT, is common in adult IOD with higher prevalence in TMI than HC. Ca/P ratio <2.32 is accurate to screen for overt/subclinical HPT and should be periodically evaluated in IOD to early detect an unbalanced mineral metabolism, and to monitor a possible evolution from subclinical to overt HPT.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"1257-1266"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Better cardiometabolic/inflammatory profile is associated with differences in the supraclavicular adipose tissue activity of individuals with T2DM.","authors":"Ivan Luiz Padilha Bonfante, Higor da Silva Segantim, Kauê Neto Soares Mendonça, Murilo Augusto Belmiro de Oliveira, Milena Monfort-Pires, Renata Garbellini Duft, Keryma Chaves da Silva Mateus, Mara Patricia Traina Chacon-Mikahil, Celso Darío Ramos, Licio Augusto Velloso, Cláudia Regina Cavaglieri","doi":"10.1007/s12020-024-04122-6","DOIUrl":"10.1007/s12020-024-04122-6","url":null,"abstract":"<p><strong>Purpose: </strong>Brown adipose tissue (BAT), located in the supraclavicular region, has been associated with a better cardiometabolic profile and reduced risk of developing non-communicable chronic diseases (NCD), in addition to being associated with a healthier phenotype in obesity. However, it is unknown whether greater supraclavicular adipose tissue activity could be associated with a healthier metabolic profile in people already diagnosed with type 2 diabetes (T2DM). Thus, the present work evaluated if supraclavicular adipose tissue activity is associated with metabolic and molecular markers in individuals with T2DM.</p><p><strong>Methods: </strong>Based on a cluster study, individuals with T2DM were divided into groups according to high or low-standard uptake value (SUV) evaluated in the supraclavicular adipose tissue area by [18F]-fluorodeoxyglucose and positron emission tomography-computed tomography (¹⁸F-FDG-PET/CT) after mild cold exposure). Functional, biochemical, inflammatory, and molecular markers were measured.</p><p><strong>Results: </strong>When we evaluated the whole sample, women showed higher SUV, which favored a difference between groups in sex-related markers. On the other hand, volunteers in the high-SUV group showed lower BMI, monocytes count, triglycerides/glucose index (TYG-index) and z score of metabolic syndrome (MS) values, as well as lower triglycerides, and VLDL concentrations. Moreover, they also had enhanced expression of thermogenic genes in subcutaneous fat. When analyzing only women, the differences in markers associated with sex disappear, and a lower count of leukocytes, platelets, along with lower TYG-index, z score of MS values, and triglycerides, VLDL, LDL, and TNFα concentrations were observed in women with the high SUV. In addition, higher expression of thermogenic genes and BECN1 were detected.</p><p><strong>Conclusion: </strong>Higher supraclavicular adipose tissue SUV in individuals with T2DM is associated with a better cardiometabolic/inflammatory profile and expression of thermogenic genes.</p><p><strong>Clinical trial registration: </strong>UTN: U1111-1202-1476 - 08/20/2020.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"1011-1021"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of ACR TI-RADS performance in transition age: results from a multicenter retrospective study by the TALENT study group.","authors":"Giorgio Grani, Ilaria Stramazzo, Pietro Locantore, Camilla Virili, Tiziana Filardi, Claudio Lecis, Roberta Centello, Gianluca Cera, Maria Giulia Santaguida, Daniele Gianfrilli, Andrea M Isidori, Cosimo Durante, Carlotta Pozza","doi":"10.1007/s12020-024-04117-3","DOIUrl":"10.1007/s12020-024-04117-3","url":null,"abstract":"<p><strong>Purpose: </strong>Although thyroid nodules are less common in the pediatric population, the risk of malignancy is higher than in adult patients. The aim of this study was to evaluate the ultrasonographic predictive factors of malignancy in thyroid nodules and to validate American College of Radiologists (ACR) TI-RADS performance in transition age patients.</p><p><strong>Methods: </strong>One hundred forty-two patients aged between 14 and 21 years referred to the participating centers for FNA biopsy of a thyroid nodule between 2007 and 2022 were included and ultrasound reports and sonographic images were retrospectively analyzed. Nodule features were defined according to the ACR-TIRADS lexicon. Two reference standards were applied: FNA cytology and surgical histology. The diagnostic performance of single sonographic features was estimated. Significant predictors were then included in a multivariate regression model.</p><p><strong>Results: </strong>Nodules included in ACR-TIRADS categories TR4 or TR5 had 10-fold increased risk of indeterminate or suspicious/malignant cytology [p < 0.001]. In univariate analysis, solid composition [p = 0.016] and presence of hyperechoic foci [p = 0.040] significantly increased the likelihood of malignant histology. In multivariate regression analysis, irregular margins [p = 0.011] and hyperechoic foci [p = 0.019] were independent predictors of indeterminate or suspicious/malignant cytology.</p><p><strong>Conclusion: </strong>Nodules included in ACR-TIRADS categories TR4 or TR5 had 10-fold increased risk of indeterminate or suspicious/malignant cytology in transition age. ACR-TIRADS was not able to rule-out malignancy compared to FNAB alone, suggesting the need to reconsider recommendations in the transition age group.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"1131-1140"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the frequency and risk factors for colorectal cancer in acromegaly.","authors":"B Maia, E Madeira, M R Gadelha, L Kasuki","doi":"10.1007/s12020-024-04099-2","DOIUrl":"10.1007/s12020-024-04099-2","url":null,"abstract":"<p><strong>Introduction: </strong>Acromegaly is associated with a possible increased risk of neoplasias, like colorectal cancer (CRC), although magnitude of this risk is unclear.</p><p><strong>Objectives: </strong>Evaluate frequency of colonic adenomatous polyps and CRC in patients with acromegaly at first and subsequent colonoscopies; correlate risk factors of CRC and disease activity of acromegaly with colonoscopy findings and analyze relationship of acromegaly as a risk factor for CRC and the best period for screening this neoplasia.</p><p><strong>Methods: </strong>Patients ≥18 years-old with acromegaly were included. A questionnaire involving characteristics of follow-up of acromegaly and risk factors of CRC was created. Biochemical and colonoscopic data were collected through medical records. Only full-length colonoscopies with satisfactory colonic preparation were included.</p><p><strong>Results: </strong>123 patients (77 women) were included (mean age at diagnosis of 43.1 years and mean follow-up of 13.7 years). In baseline colonoscopy, 80.5% had non-neoplastic findings, 14.6% non-advanced adenomas, 3.3% advanced adenomas and 1.6% CRC. At end of the study, 3 (2.4%) patients were diagnosed with CRC. No patient under 50 years had a neoplastic lesion on colonoscopy. We observed a positive statistically significant relationship between smoking (p = 0.026), age at diagnosis of acromegaly (p < 0.001), age at baseline colonoscopy (p = 0.002), and risk of adenomas and/or CRC at initial colonoscopy.</p><p><strong>Conclusions: </strong>Smoking and advanced age were positively related to a higher risk of developing premalignant/malignant colonic lesions. Age ( > 50 years) was the most robust variable. Our data suggest that screening age for CRC in acromegaly should be reviewed.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"1162-1170"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study.","authors":"Antonella Al Refaie, Leonardo Baldassini, Caterina Mondillo, Elena Ceccarelli, Roberto Tarquini, Luigi Gennari, Stefano Gonnelli, Carla Caffarelli","doi":"10.1007/s12020-024-04085-8","DOIUrl":"10.1007/s12020-024-04085-8","url":null,"abstract":"<p><strong>Purpose: </strong>Type 2 diabetes mellitus (T2DM) stands as the most prevalent metabolic disorder globally. T2DM entails numerous cardiovascular complications, which contribute significantly to morbidity, mortality, and increased public spending worldwide. The real challenge for new diabetes drugs lies not only in reducing blood glucose levels and glycated hemoglobin but also in preventing cardiovascular risk. Emerging receptor agonists for glucagon-like peptide-1 (GLP-1RAs) have demonstrated a pivotal role in diabetes management and mitigating cardiovascular risk.</p><p><strong>Methods: </strong>We conducted a 12-month longitudinal investigation evaluating the cardio-metabolic effects of GLP-1RAs on a cohort of 65 Caucasian patients diagnosed with T2DM who were scheduled for treatment with GLP-1RAs. Fifty-four T2DM patients successfully completed the 12-month study period, with 30 receiving dulaglutide and 24 receiving semaglutide.</p><p><strong>Results: </strong>In our study population, GLP-1RAs resulted in several positive changes beyond the observed weight loss: a shift in fat distribution, indicated by a reduction in the percentage of visceral fat (1.21 vs. 1.17, p < 0.05); a significant decrease in LDL cholesterol levels (p < 0.05) and triglycerides (p < 0.01); and a significant increase in serum adiponectin levels (p < 0.05), potentially indicating a reduction in insulin resistance and inflammation. Additionally, we observed a significant decrease in microalbuminuria and media-intimal thickness at the carotid vessel level (p < 0.05).</p><p><strong>Conclusions: </strong>In patients with T2DM 1-year therapy with GLP-1RAs has a positive effect on the main determinants of cardiovascular risk including body weight, visceral fat, dyslipidemia, and atherosclerosis. Moreover, the increase in adiponectin may play a pivotal role in controlling the inflammatory state and the mechanisms of vascular damage.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"951-958"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells.","authors":"Giusy Elia, Silvia Martina Ferrari, Iryna Tkachenko, Dipak Walunj, Eugenia Balestri, Chiara Botrini, Francesca Ragusa, Alessandro Antonelli, Gary Gellerman, Poupak Fallahi","doi":"10.1007/s12020-024-04088-5","DOIUrl":"10.1007/s12020-024-04088-5","url":null,"abstract":"<p><strong>Purpose: </strong>New drugs are needed for the therapy of anaplastic thyroid cancer (ATC). This study aims to investigate doxorubizen (a dual-action structural hybrid (chimera) of doxorubicin (Dox) and DNA methylating drug temozolomide), in comparison with Dox, and alone or in combination with lenvatinib in ATC 8305C cells, and in primary human ATC cell cultures (pATC).</p><p><strong>Methods: </strong>We have investigated doxorubizen, Dox, and lenvatinib on 5 different pATC and in continuous 8305C cell line in vitro, evaluating their effect on cells proliferation by WST-1, apoptosis (Hoechst ad Annexin V assays) and migration (Chemicon QCM™ 96-well Migration Assay).</p><p><strong>Results: </strong>The results have demonstrated: (1) a significant antiproliferative and proapoptotic effect of doxorubizen in 8305C and in pATC; (2) a significant antiproliferative and proapoptotic effect of Dox in pATC, and in 8305C; (3) the antineoplastic effect of lenvatinib in 8305C and in pATC; (4) a stronger antiproliferative and proapoptotic effect of doxorubizen than that of Dox, or lenvatinib; (5) that doxorubizen induced an inhibition of migration in pATC stronger than that of Dox, or lenvatinib; (6) that doxorubizen is able to synergize in vitro with lenvatinib increasing the antiproliferative effect, while doxorubizen alone is the primary factor that promotes the proapoptotic impact.</p><p><strong>Conclusion: </strong>We have first shown that doxorubizen has a potent antineoplastic effect in vitro in 8305C and in 5 different pATC, and that can synergize with lenvatinib. These results open the way to a future evaluation of the antineoplastic effect of doxorubizen in ATC patients.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"1050-1059"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycomic profiling of parathyroid neoplasms via lectin microarray analysis.","authors":"Qingyuan Zheng, Ming Cui, Jinheng Xiao, Sen Yang, Tianqi Chen, Yanan Shi, Ya Hu, Quan Liao","doi":"10.1007/s12020-024-04107-5","DOIUrl":"10.1007/s12020-024-04107-5","url":null,"abstract":"<p><strong>Purpose: </strong>Parathyroid carcinoma (PC) is a rare malignancy with a poor prognosis. Diagnosis of PC is often difficult in clinical practice and efficient diagnostic markers are still needed for differential diagnosis. Aberrant glycosylations of glycoproteins were identified with lectin microarray in various cancers, while relevant information is lacking in PC.</p><p><strong>Methods: </strong>In this study, 8 PC and 6 parathyroid adenoma (PA) tissues were assessed using a microarray consisting of 70 lectins. Overall lectin-specific glycosylation patterns were compared between PA and PC tissues. Lectins with significant differential response between PC and PA were further validated by lectin histochemistry.</p><p><strong>Results: </strong>The difference in signal intensities was found in 71.4% (50/70) of the lectins between the two groups (P < 0.05). The vast majority of PCs had higher intensity signals than PAs (PCs vs. PAs, ratio >1) and amaranthus caudatus (ACL) showed the most significantly different response between them (ratio = 2.45). Lectin histochemistry further confirmed higher ACL intensity in PCs than in PAs. The differentially expressed glycans in PC tissues were primarily glucose, mannose, and galactose-based.</p><p><strong>Conclusion: </strong>PC presented unique glycomic features and ACL may serve as a candidate diagnostic marker for PC.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"1224-1234"},"PeriodicalIF":3.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}